

## Special Issue

# Antimicrobial Peptides Aka Host Defense Peptides – from Basic Research to Therapy

### Message from the Guest Editor

All wounds are at risk of becoming contaminated by pathogens, which could lead to infection. The ability to effectively overcome this danger is of evolutionary significance to our survival. It is therefore not surprising that multiple host defense systems, such as host defense peptides, have evolved. Antimicrobial peptides, aka host-defense peptides (HDPs), display activity against bacteria, fungi, viruses, and parasites. Today we have clear evidence that HDPs have far more than broad-spectrum antimicrobial activity, including immunomodulatory effects, wound healing, LPS neutralization, chemotaxis, or anti-cancer effects. Moreover, the multifunctionality of HDPs puts a lot of interest in the development of new therapeutic strategies against infectious diseases. This Special Issue will address the most current and innovative developments in the field of HDPs research with a range of topics such as structure and function analysis, modes of action, anti-microbial effects, cell and animal model systems, the discovery of novel host defense peptides, and drug development.

- antimicrobial peptides
- host defense peptides
- innate immunity
- wound healing

---

### Guest Editor

Dr. Jitka Petrlova

Department of Clinical Sciences, Division of Dermatology and Venereology, Lund University, Lund, Sweden

---

### Deadline for manuscript submissions

closed (31 May 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/105817](https://mdpi.com/si/105817)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).